Source comparison
TB-500 Research Focus Considerations: Peptide vs Control Comparison
Peptide Stability (Lyophilized) Stable at −20°C for 24+ months; sensitive to moisture ingress Stable at −20°C for 18–24 months; similar moisture sensitivity Highly stable at −20°C for 36+ months; less prone to oxidation TB-500's shorter sequence makes it sligh
This comparison does not assign a generated winner or score.
- Peptide Stability (Lyophilized)
- Stable at −20°C for 24+ months; sensitive to moisture ingress
- Stable at −20°C for 18–24 months; similar moisture sensitivity
- Highly stable at −20°C for 36+ months; less prone to oxidation
- TB-500's shorter sequence makes it slightly more stable than full TB4 but less stable than BPC-157. Moisture control during storage is critical for all three
- Reconstitution Shelf Life
- 28 days at 2–8°C; significant potency loss beyond 4 weeks
- 21–28 days at 2–8°C; aggregation risk increases after 3 weeks
- 28–35 days at 2–8°C; maintains potency longer in solution
- TB-500 and BPC-157 have comparable reconstituted shelf lives. Full TB4's larger structure makes it more prone to aggregation in solution
- Dosing Route Sensitivity
- Subcutaneous produces 60–70% bioavailability vs intraperitoneal
- Subcutaneous produces similar 60–70% bioavailability
- Subcutaneous and oral both demonstrate activity (rare for peptides)
- All three require route-specific dosing adjustments. BPC-157's oral bioavailability is unique and not shared by TB-500 or TB4
- Species Scaling Factor
- Rodent clearance 2–3× faster than human; equine similar to human
- Rodent clearance 2–3× faster; equine data limited
- Rodent and human clearance rates more similar (1.5× difference)
- TB-500 and TB4 require significant dose adjustment for rodent models. BPC-157's pharmacokinetics are more consistent across species
- Third-Party Testing Availability
- HPLC and LC-MS available from multiple contract labs ($150–$300/sample)
- HPLC available; LC-MS less common due to larger peptide size
- HPLC and LC-MS widely available; standard testing protocols established
- All three can be verified independently. TB-500's smaller size makes mass spec identification slightly easier than full TB4
- Bottom Line
- TB-500 offers better stability and easier verification than full TB4, but requires strict cold-chain management and species-specific dosing adjustments to match the reproducibility of more stable peptides like BPC-157
- Full TB4 provides the native sequence but with higher aggregation risk and comparable stability challenges to TB-500
- BPC-157 demonstrates superior solution stability and broader route flexibility, making it easier to work with in multi-week protocols despite different mechanisms
- For tissue repair research requiring 8+ week dosing protocols, TB-500's cold-chain sensitivity and reconstituted shelf life create more failure points than BPC-157. Choose TB-500 when the actin-binding mechanism is specifically required, otherwise consider more stable alternatives